Summary
Rabies Vaccine prepared in MRC-5 diploid cells from Connaught Laboratories’ virus seed CL-77 was administered to almost 700 adults for primary, reinforcement and post-exposure immunization.
Subjects were immunized using several schedules and results are presented in detail. All subjects responded with acceptable antibody titres. Close monitoring of vaccinees demonstrated a considerable reduction in vaccine side effects with increased purification of the vaccine. No serious side effect occurred in any vaccinee.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Seligmann EB Jr (1973) The NIH test for potency. Laboratory Techniques in Rabies. World Health Organization, Geneva, third Ed, chap 33, pp 279–286
Smith JS, Yager PA, Baer GM (1973) A rapid reproducible test for determining rabies neutralizing antibody. Bulletin of the World Health Organization, 48:535–541
Zalen E, Wilson C, Pukitis D (1979) A microtest for the quantitation of rabies virus neutralizing antibodies. J of Biol Standard 7:213–220
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin, Heidelberg
About this paper
Cite this paper
Johnson, S.E., Pearson, E.W., Ing, W.K. (1985). Clinical Responses in Humans to Rabies Vaccine Prepared in MRC-5 Diploid Cells from Canadian Seed Virus. In: Kuwert, E., Mérieux, C., Koprowski, H., Bögel, K. (eds) Rabies in the Tropics. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70060-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-70060-6_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13826-6
Online ISBN: 978-3-642-70060-6
eBook Packages: Springer Book Archive